Once-daily topical brimonidine tartrate gel 0.5% is a novel treatment of moderate to severe facial erythema of rosacea: results of two multicenter, randomized and vehicle-controlled studies
British Journal of Dermatology, 11/03/2011
Fowler J et al. – No tachyphylaxis, rebound of erythema or aggravation of other disease signs (telangiectasia, inflammatory lesions) was observed. All regimens were safe and well–tolerated with similarly low incidence of adverse events. Once–daily Brimonidine tartrate(BT) gel 0.5% is well–tolerated and provides significantly greater efficacy than vehicle gel for the treatment of moderate to severe erythema of rosacea.